scholarly journals Trigeminal Zoster with drug-induced labial angioedema leading to necrosis

Author(s):  
David Tyler Coyle

Introduction. Zoster is caused by the reactivation of a dormant viral infection, and is characterized by painful, vesicular lesions along a dermatome. Neuritic pain associated with zoster can be treated with anticonvulsant medications. Case Report. An immunocompetent adult physician developed prominent zoster lesions in the trigeminal nerve distribution. Treatment included antiviral therapy for the acute infection, and pharmacotherapy for neuritic pain. Pharmacotherapy included several anticonvulsant agents, with labial angioedema developing after initiation of oxcarbazepine. Discussion. The case is notable for the pictorial timeline of lesion development, as well as the marked incident angioedema following initiation of treatment for neuritis with oxcarbazepine. Conclusions. Clinicians should remain vigilant for drug-induced facial angioedema when treating patients with trigeminal zoster-related neuritis due to the potential for angioedema to aggravate a lesion, resulting in scarring. Angioedema of the head and neck should be closely monitored due to the potential for airway compromise.

2014 ◽  
Vol 8 (1) ◽  
Author(s):  
Giovanni Dell’Aversana Orabona ◽  
Giorgio Iaconetta ◽  
Vincenzo Abbate ◽  
Pasquale Piombino ◽  
Antonio Romano ◽  
...  

Reports ◽  
2021 ◽  
Vol 4 (1) ◽  
pp. 5
Author(s):  
Sawako Ono ◽  
Takuma Makino ◽  
Hiroyuki Yanai ◽  
Hotaka Kawai ◽  
Kiyofumi Takabatake ◽  
...  

Spindle cell carcinoma (SCSCC) with osteoid and/or cartilage formation in the head and neck is rare; only one case was reported in the tongue. Herein, we report an SCSCC with osteoid and cartilage formation of the tongue developed in an 85-year-old man, and then review the report.


2021 ◽  
Vol 22 (12) ◽  
pp. 6480
Author(s):  
Céline K. Stäuble ◽  
Markus L. Lampert ◽  
Thorsten Mikoteit ◽  
Martin Hatzinger ◽  
Kurt E. Hersberger ◽  
...  

We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and 400 mg. The extensive hepatic metabolism of quetiapine is mainly attributed to cytochrome P450 3A4 (CYP3A4). However, there is recent evidence supporting the idea of CYP2D6 playing a role in the clearance of the quetiapine active metabolite norquetiapine. Interestingly, both patients we are reporting of are carriers of the CYP2D6*4 variant, predicting an intermediate metabolizer phenotype. Additionally, co-medication with a known CYP2D6 inhibitor and renal impairment might have further affected quetiapine pharmacokinetics. The herein reported cases could spark a discussion on the potential impact of a patient’s pharmacogenetic predisposition in the treatment with quetiapine. However, further studies are warranted to promote the adoption of pharmacogenetic testing for the prevention of drug-induced toxicities associated with quetiapine.


2021 ◽  
Vol 82 ◽  
pp. 105907
Author(s):  
Nandi Viljoen ◽  
Gerrit Viljoen ◽  
Johannes J. Fagan ◽  
Dhirendra Govender
Keyword(s):  

2021 ◽  
pp. 100330
Author(s):  
Alyssa Ovaitt ◽  
Matthew Fort ◽  
Kirk Withrow ◽  
Brian Hughley

Author(s):  
Olufolakemi Awe ◽  
Peter Pavlidakey ◽  
Lauren Kole ◽  
Rebecca Kissel

Sign in / Sign up

Export Citation Format

Share Document